- PATIENT PLANS
- ABOUT US
- CONTACT US
Caregivers, cancer patients, and loved ones, you can watch this webinar about childhood cancer by Dr. Jason Freedman, Dr. Gerald Wertheim and Dr. Sarah Tasian.
If you missed the webinar, you can still watch the recording here.
Caregivers, patients, and loved ones joined Dr. Belisario Arango and Dr. Arturo Loaiza-Bonilla on Monday, June 19, 12 pm EDT for this very informative and interactive question and answer panel format webinar.
Our doctors answered participants questions submitted during the webinar and ones that have been sent to Massive Bio.
Bringing state-of-the-art precision cancer care was aired Tuesday, March 14 at 12:00 EDT.
Dr. Belisario Arango covered the following topics:
Why there is a higher cancer prevalence in patients in rural areas?
What are the challenges delivering cancer care to patients?
Where is the future of cancer care going?
September 19, 2017
Much has been said and written about the lack of women in the tech sector, be it as investors (or associates), founders, or in management positions at major companies. Is the problem the old boys network – or that success in technology is seen as a young man’s game? In this series, we speak with some of the top women in tech in New York as they discuss the challenges they face, the perceptions that need to be changed and the work that’s being done – or not – to help to promote women in tech.
Today we speak with Dr. Selin Kurnaz, CEO and cofounder of Massive Bio. After emigrating from Turkey and completing a PhD at the University of Michigan, receiving multiple engineering degrees, Selin spent more than a specializing in delivering revenue enhancement, margin optimization and capital efficiency improvements for Pharmaceutical and Life Science companies. Her startup, Massive Bio, brings the latest knowledge in cancer care to patients treated at community practices in the US and worldwide. Selin has written and spoke extensively about life sciences in tech and how to deliver information in creative ways.
Into Global Business Communications Co., Ltd. (INTO) organized the first AI & big data health tech program successfully in New York this April.
On June 27, 2017, a member of the Massive Bio Team, Belisario A. Arango, M.D., took part of the Cancer Moonshot Project and the Biden Cancer Initiative Meeting in Washington, D.C. The meeting was hosted by Kim Thiboldeaux, CEO of Cancer Support Community and a member of the Board of Directors of the Biden Cancer Initiative. The purpose of this meeting was to update the cancer community on the accomplishments over the past year, since the announcement of the Moonshot challenge, and to discuss the goals that are expected to be reached over the next 4 years.
For Latin America, headquartered in Colombia, home of regional nascent IT and startup boom, Massive Bio will now broadcast in Caracol International which reaches to 14+ million subscribers.
Before starting a clinical trial, doctors must prove there is a chance that the new treatment or procedure will work better than what is currently available. They do research until they can prove this.
Groop served on the Avera Rural Cancer Advisory Board charged with raising awareness of the resources available to patients and families who face cancer. She is aware of the challenges because her sister faced cancer.
Keeping track of all of the financial paperwork involved in your cancer care can quickly become overwhelming. Below are 4 ways you can stay organized and take control of that information.
The rate of new cancer cases has decreased in the United States since the 1990s. But increases in overweight- and obesity-related cancers—which now account for 40% of all U.S. cancers—are likely slowing that progress, according to a new report from the Centers for Disease Control and Prevention (CDC).
Nivolumab and ipilimumab are immune checkpoint inhibitors that have been approved for the treatment of advanced melanoma. In the United States, ipilimumab has also been approved as adjuvant therapy for melanoma on the basis of recurrence-free and overall survival rates that were higher than those with placebo in a phase 3 trial. The researchers wanted to determine the efficacy of nivolumab versus ipilimumab for adjuvant therapy in patients with resected advanced melanoma.
Combination therapy with the BRAF inhibitor dabrafenib plus the MEK inhibitor trametinib improved survival in patients with advanced melanoma with BRAF V600 mutations. It was sought to determine whether adjuvant dabrafenib plus trametinib would improve outcomes in patients with resected, stage III melanoma with BRAF V600 mutations.
Liver cancer is among the leading causes of cancer deaths globally. The most common causes for liver cancer include hepatitis B virus (HBV) and hepatitis C virus (HCV) infection and alcohol use.
Cancer researchers have discovered a new class of fusion genes with properties that affect and may drive the development of cancer.
Cancer patients, caregivers and oncologists - we would like to introduce ourselves as your next step toward fighting cancer. Massive Bio, Inc., headquartered in New York, is an innovative digital health company that brings the latest and greatest in cancer care to the point of need.